One Stop Shop For Reports One Stop Shop For Reports
  • Reports
  • Press Release
  • Statistics
  • About Us
  • [email protected]
  • +1 718 874 1545 (International)
  • +91 78878 22626 (Asia)

More Results

One Stop Shop For Reports One Stop Shop For Reports
  • Reports
  • Press Release
  • Statistics
  • About Us
Home ➤ Press Releases ➤ Traws Pharma Defers Phase 2a Influenza Study After Negative MHRA Review
Traws Pharma Defers Phase 2a Influenza Study After Negative MHRA Review
Traws Pharma Defers Phase 2a Influenza Study After Negative MHRA Review
  • Home ➤ Press Releases ➤ Traws Pharma Defers Phase 2a Influenza Study After Negative MHRA Review

Traws Pharma Defers Phase 2a Influenza Study After Negative MHRA Review

Traws Pharma

Quick Navigation

  • TXM Shows Activity in Bird Flu Animal Studies
  • Alternative Influenza Candidates Are Advancing
  • Influenza Prevention Remains a Research Priority
  • Company Expects Funding to Support Operations Into Q1 2027
  • About Traws Pharma

Traws Pharma, Inc. has deferred a planned Phase 2a human influenza challenge study of tivoxavir marboxil, known as TXM, following a negative review of the program by the United Kingdom’s Medicines and Healthcare Products Regulatory Agency (MHRA).

In its June 12, 2026 announcement, the company said influenza treatment and prevention remain a priority. It is advancing alternative antiviral candidates intended to preserve TXM’s long-lasting activity while avoiding mutagenic potential.

TXM Shows Activity in Bird Flu Animal Studies

C. David Pauza, PhD, Chief Science Officer at Traws Pharma, said TXM demonstrated potent efficacy in three animal models of highly pathogenic avian influenza. He also described the candidate’s pharmacokinetic profile as consistent with potential use in bird flu treatment and prevention.

These are company-reported animal findings, not results from the planned human influenza challenge study. Pauza said TXM retains potential for emergency use during a bird flu outbreak and for prevention in high-risk populations. His comments describe possible future applications rather than an authorized use.

Alternative Influenza Candidates Are Advancing

Traws Pharma said it has a portfolio of backup influenza antiviral compounds. The company is advancing candidates designed to maintain TXM’s long-duration pharmacokinetic and antiviral characteristics while avoiding mutagenic potential.

Chief Executive Officer Iain Dukes said the regulatory feedback affects the timing of the planned challenge study but does not change the company’s confidence in the underlying scientific rationale. He also highlighted the potential role of long-acting antivirals in seasonal influenza prevention.

Influenza Prevention Remains a Research Priority

Robert R. Redfield, MD, Chief Medical Officer at Traws Pharma and former Director of the U.S. Centers for Disease Control and Prevention, described influenza, including bird flu, as a continuing public health threat.

While acknowledging the setback involving TXM, Redfield emphasized the importance of treatment and prevention for older adults and people with weakened immune systems, who face a greater risk of severe influenza.

Company Expects Funding to Support Operations Into Q1 2027

Dukes said Traws Pharma’s cash runway extended into the first quarter of 2027. This estimate reflected management’s expectations at the time of the June announcement.

The company plans to continue developing alternative influenza candidates while addressing potential regulatory concerns. Its forward-looking disclosures identify risks that could affect development, including regulatory decisions and its ability to advance drug candidates.

Separately, those disclosures reference an existing U.S. Food and Drug Administration clinical hold associated with TXM’s Investigational New Drug filing. That U.S. regulatory matter is distinct from the MHRA review that prompted the deferral of the planned UK challenge study.

About Traws Pharma

Traws Pharma is a clinical-stage biopharmaceutical company based in Newtown, Pennsylvania. It develops investigational oral small-molecule antiviral medicines targeting difficult-to-treat or resistant viral strains.

Its development activities address seasonal influenza, H5N1 bird flu, COVID-19, and Long COVID, as well as potential treatments for Hantavirus infections, Ebola virus disease, and Lassa fever. The company combines antiviral drug development, medical intelligence, and regulatory strategy in its research programs.

Related Press Releases

  • TechnoVision: Top 5 Tech Trends to Watch in 2027 By Capgemini
  • AGC Biologics Welcomes Multiple Cell Therapy Projects at Its New Yokohama Facility
  • BlackLine Launches Availability on Anthropic’s Claude Marketplace
  • Mobilicom Announces Participation in Upcoming Industry and Investor Conferences
  • AI Errors Strain Business Finances and Delay Projects Worldwide
  • Neurosterix, an Addex Spin-Out, Closes $105 Million Series B Financing
Latest report from the featured industries
  • Advanced Materials
    Optical Coating Market
    Spray Drying Equipment Market
    Metal Roofing Market
    Stone And Tile Adhesives And Sealants Market
    Armor Materials Market
    PTFE Hoses Market
    Roofing Materials Market
    Acrylic Foam Tape Market
    Oil Shale Market
    Pine-Derived Chemicals Market
  • Aerospace and Defence
    Satellite Launch Systems Market
    Satellite Communication In The Defense Sector Market
    Lyocell Fabric Market
    Bullet Proof Jacket Market
    Rescue Pole Market
    Police Baton Market
    Drone Battery Market
    Gunshot Detection System Market
    Military Electro-optical And Infrared Systems Market
    Multirotor Drone Market
  • Agriculture & Agri Products
    Mooring Systems Market
    Oilseed Processing Market
    Cut Flowers Market
    Cotton Processing Market
    Farm Equipment Rental Market
    Agricultural Variable Rate Technology Market
    Indoor Farming Technology Market
    Essential Oils And Plant Extract For Livestock Market
    Food Vacuum Machine Market
    Ornamental Horticulture Market
  • Apparel | Fashion & Accessories
    3D Printed Jewelry Market
    Cotton (Linter) Pulp Market
    Snow Boots Market
    Merchandise Designing Market
    Volleyball Shoes Market
    Smart Clothing Market
    Workwear Market
    Down Jacket Market 
    Decorated Apparel Market
    Dancewear Market
  • Artificial Intelligence
    AI-Based Defect Detection Software Market
    AI Vision For Manufacturing Market
    AI Training Data Lineage Software Market
    AI Portfolio And Pipeline Management Software Market
    AI In Testing Inspection And Certification Market
    Agentic AI Market
    AI In Telecommunication Market
    AI In Materials Science Market
    AI Data Labeling Market
    AI Data Center Power Consumption Market
✖
Request a Sample Report
We'll get back to you as quickly as possible
CAPTCHA Code

✖
Request a Sample Report
We'll get back to you as quickly as possible
CAPTCHA Code

  • location_on420 Lexington Avenue, Suite 300 New York City, NY 10170,
    United States
  • phone+1 718 874 1545 (International)
  • phone+91 78878 22626 (Asia)
  • email[email protected]
  • Facebook Logo
  • Twitter Logo
  • LinkedIn Logo
Find Help
  • Contact Us
  • How to Order
Legal
  • Privacy Policy
  • Refund Policy
  • Frequently Asked Questions
  • Terms and Conditions
Explore
  • About Us
  • Our Clients
  • Media Mentions
  • Infographics
  • Statistics and Facts
  • Research Methodology
  • Why Choose Us?
Secured Payment Options
Secured Payment Options

© 2026 Market.Us. All Rights Reserved.